KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) Interest Expenses: 2018-2025

Historic Interest Expenses for Elanco Animal Health (ELAN) over the last 7 years, with Sep 2025 value amounting to $52.0 million.

  • Elanco Animal Health's Interest Expenses fell 10.34% to $52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.0 million, marking a year-over-year decrease of 27.34%. This contributed to the annual value of $235.0 million for FY2024, which is 15.16% down from last year.
  • According to the latest figures from Q3 2025, Elanco Animal Health's Interest Expenses is $52.0 million, which was up 8.33% from $48.0 million recorded in Q2 2025.
  • Elanco Animal Health's 5-year Interest Expenses high stood at $74.0 million for Q2 2023, and its period low was $40.0 million during Q1 2025.
  • Moreover, its 3-year median value for Interest Expenses was $64.0 million (2023), whereas its average is $59.3 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 281.25% in 2021, then plummeted by 39.39% in 2025.
  • Quarterly analysis of 5 years shows Elanco Animal Health's Interest Expenses stood at $55.0 million in 2021, then grew by 12.73% to $62.0 million in 2022, then grew by 8.06% to $67.0 million in 2023, then slumped by 31.34% to $46.0 million in 2024, then declined by 10.34% to $52.0 million in 2025.
  • Its Interest Expenses was $52.0 million in Q3 2025, compared to $48.0 million in Q2 2025 and $40.0 million in Q1 2025.